CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy

Tomaz, Paulo Roberto Xavier; Santos, Juliana Rocha; Issa, Jaqueline Schölz; Abe, Tânia Ogawa; Gaya, Patrícia Viviane; Pereira, Alexandre C.; Santos, Paulo Caleb Júnior Lima

doi:10.1007/s00228-015-1896-x

Cited by 27 publications

(28 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These expectations may exceed the evidence supported by the present literature. It should be noted the use of pharmacogenetic testing as well as nicotine metabolic ratio has only just begun to predict successful smoking cessation in general [15][16][17][18]20,21], and has yet to be shown to do so in the AI/AN population specifically. However, the few concrete examples of pharmacogenetic testing altering clinical outcomes offer promise to cessation treatment adherence [16,17,42].…”

Section: Discussionmentioning

confidence: 99%

“…Wide pharmacogenetic variation across racial and ethnic groups contributes to interindividual differences in drug metabolism, with implications for drug dosing, medication response and toxicity [19]. Particular genetic variants of CYP2A6, CYP2B6, CHRNA5-A3-B4, CHRNB2, CHRNA5, CHRNA4 as well as nico tine metabolic ratio, a genetically informed biomarker, have been found to predict successful smoking cessation and response to pharmacotherapy (e.g., nicotine replacement therapy, varenicline, bupropion) [15][16][17][18]20,21]. AI/AN people have been historically underrepresented in medical research and may be less likely to benefit from current pharmacogenetic research and recommendations [19,[22][23][24].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perceptions of Pharmacogenetic Research to Guide Tobacco Cessation by Patients, Providers and Leaders in a Tribal Healthcare Setting

et al. 2016

View full text Add to dashboard Cite

Aim: Describe patients,' providers' and healthcare system leaders' perceptions of pharmacogenetic research to guide tobacco cessation treatment in an American Indian/Alaska Native primary care setting. Materials & methods: This qualitative study used semistructured interviews with 20 American Indian/Alaska Native current or former tobacco users, 12 healthcare providers and nine healthcare system leaders. Results: Participants supported pharmacogenetic research to guide tobacco cessation treatment provided that a community-based participatory research approach be employed, research closely coordinate with existing tobacco cessation services and access to pharmacogenetic test results be restricted to providers involved in tobacco cessation. Conclusion: Despite a history of mistrust toward genetic research in tribal communities, participants expressed willingness to support pharmacogenetic research to guide tobacco cessation treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Perceptions of Pharmacogenetic Research to Guide Tobacco Cessation by Patients, Providers and Leaders in a Tribal Healthcare Setting

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In contrast to variants that decrease the function of CYP2B6, the CYP2B6*4 allele is associated with increased CYP2B6 activity . One study has suggested that carriers of the CYP2B6*4 allele have lower smoking cessation success rates (35.5%) compared to wild type (48%) …”

Section: Resultsmentioning

confidence: 99%

“…35 One study has suggested that carriers of the CYP2B6*4 allele have lower smoking cessation success rates (35.5%) compared to wild type (48%). 55…”

Section: Influence Of Cyp2b6 Genetic Variation On Pharmacodynamics mentioning

confidence: 99%

Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation

2018

View full text Add to dashboard Cite

Summary What is known and objective Pharmacogenomics holds promise in smoking cessation because of its potential to shed light on the complexity of drug metabolism and improve treatments using therapeutic agents. The cytochrome P450 2B6 gene (CYP2B6) encodes CYP2B6 enzyme that has been found to mediate the hydroxylation of bupropion, a smoking cessation aid. CYP2B6 exhibits a range of polymorphic variants that alter the pharmacokinetics and pharmacodynamics of bupropion. Genetic variations in CYP2B6 may influence the risk of adverse effects or efficacy of treatment with bupropion. The objective of this review was to investigate the influence of pharmacogenomics on smoking cessation therapy. Methods A thorough literature search was conducted on PubMed, SCOPUS and EMBASE using keywords related to bupropion, smoking cessation, pharmacogenomics and CYP2B6. Research and review articles, case reports and clinical and preclinical studies pertinent to the research topic were identified, evaluated and summarized. Cited articles within the above‐mentioned sources also provided pertinent information. Results There is strong literature evidence to prove that CYP2B6 polymorphisms affect pharmacokinetic and pharmacodynamic properties of bupropion, thus affecting the therapeutic outcome of smoking cessation therapy. What is new and conclusions Complete understanding of pharmacogenetic variation of bupropion pharmacokinetics and pharmacodynamics will be beneficial for designing safer and more personalized smoking cessation therapy with improved outcomes.

show abstract

“…Likely, the CYP2B6*4 variant influences the pharmacological activity of bupropion, and CYP2B6*4 may be a genetic marker for individualized bupropion pharmacotherapy [98]. …”

Section: Genetics Of Smoking Cessation Treatment Responsementioning

confidence: 99%

Pathways to precision medicine in smoking cessation treatments

Chen

Horton

Bierut

2018

Neuroscience Letters

View full text Add to dashboard Cite

Cigarette smoking is highly addictive and modern genetic research has identified robust genetic influences on nicotine dependence. An important step in translating these genetic findings is to identify the genetic factors affecting smoking cessation in order to enhance current smoking cessation treatments. We reviewed the significant genetic variants that predict nicotine dependence, smoking cessation, and response to cessation pharmacotherapy. These data suggest that genetic risks may predict smoking cessation outcomes and moderate the effect of pharmacological treatments. Some pharmacogenetic findings have been replicated in meta-analyses or multiple smoking cessation trials. The variation in efficacy between smokers with different genetic markers supports the notion that personalized smoking cessation intervention based upon genotype could maximize the efficiency of such treatment while minimizing side effects, thus influencing the number needed to treat (NNT) and the number needed to harm (NNH). In summary, as precision medicine is revolutionizing health care, smoking cessation may be one of the first areas where genetic variants identify individuals at increased risk. Genetic variants predict cessation failure, and this increased risk may be ameliorated by cessation pharmacotherapy.

show abstract

CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy

Cited by 27 publications

References 45 publications

Perceptions of Pharmacogenetic Research to Guide Tobacco Cessation by Patients, Providers and Leaders in a Tribal Healthcare Setting

Perceptions of Pharmacogenetic Research to Guide Tobacco Cessation by Patients, Providers and Leaders in a Tribal Healthcare Setting

Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation

Pathways to precision medicine in smoking cessation treatments

Contact Info

Product

Resources

About